Researchers at the University of Melbourne in Melbourne, Australia discovered a key step in the progression of Huntington’s disease. A genetic neurological disease that normally begins to manifest itself when patients are in their thirties and forties, Huntington’s disease has ...

The San Francisco based biopharmaceutical company Medivation has recently published results of its first pivotal clinical trial of Dimebon in Alzheimer’s disease. Dimebon, a drug formerly approved as an allergy treatment, demonstrated statistically significant improvement over placebo in memory, thinking, ...